Eli Lilly’s Trulicity (dulaglutide) Receives the US FDA’s Approval to Reduce MACE in T2D Adults
Eli Lilly’s Alimta (pemetrexed) + Keytruda (pembrolizumab) Receives FDA’s Expanded Label Approval for 1L Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
Shots:
- The approval follows the REWIND study which involves assessing of Trulicity + SoC (1.5mg) vs PBO + SoC in adults with T2D
- The study showed reduction in MACE events and the profile of Trulicity was consistent with the GLP-1 receptor agonist (RA) class
- Trulicity is an injectable prescription medicine for adults with T2D used for the improving blood sugar level and reduction of MACE
Click here to read full press release/ article | Ref: Eli Lilly | Image: Twitter